| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:LY 25648
CAS:107889-31-6
Package:100mg/RMB 17500;25mg/RMB 10600;50mg/RMB 13800
|
LY 25648 manufacturers
- LY 25648
-
- $2500.00 / 100mg
-
2025-08-21
- CAS:107889-31-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | LY 25648 Basic information |
| Product Name: | LY 25648 | | Synonyms: | LY 25648;Dihydro-3-methyl-5-(4-hydroxy-3,5-ditert-butylbenzylidene)thiazol-4(5H)-one;LY-256548;4-Thiazolidinone, 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-methyl- | | CAS: | 107889-31-6 | | MF: | C19H27NO2S | | MW: | 333.49 | | EINECS: | | | Product Categories: | | | Mol File: | 107889-31-6.mol |  |
| | LY 25648 Chemical Properties |
| | LY 25648 Usage And Synthesis |
| Description | LY 25648 is a leukotriene B4 antagonist. | | Uses | LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model[1][2]. | | in vivo | The oral absorption of LY256548 (LY25648) in rats, dogs, and monkeys was 45%, 7%, and 12%, respectively, and the systemic bioavailability was 6%, 0.4%, and 3%, respectively[1]. | | IC 50 | Cyclooxygenase; 5-LOX; PLA2; LTB4 | | References | [1] Ruterbories KJ, et al. Pharmacokinetics of a novel butylated hydroxytoluene-thiazolidinone CNS antiischemic agent LY256548 in rats, mice, dogs, and monkeys. Drug Metab Dispos. 1990 Sep-Oct;18(5):674-9. PMID:1981719
[2] Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DOI:10.1007/BF01972804 |
| | LY 25648 Preparation Products And Raw materials |
|